The Chinese People’s Court shifts the burden of proof to the defendant in a known-compound preparing process patent infringement case By Dr. Stephen ZOU* Due to lack of discovery procedure, in China, it is very difficult for the patentee to enforce a process patent, especially a process patent for a known product. In Ashland Licensing and…
The Chinese Supreme People’s Court expressly opines how to construe a close-ended claim, By Dr. Stephen ZOU* In the [2012] Civil Retrial No. 10, the Chinese Supreme People’s Court (hereinafter “SPC”) delivers its opinion regarding how to construe a close-ended claim. The patent at issue claims a freeze-dried powder injection, consisting of ATP and magnesium chloride…
Overview An Opinion drafted by the Brazilian Patent and Trademark Office (BPTO) legal department regarding the patent term for pharmaceutical products or chemical products for agriculture filed between January 1st, 1995 and May 14th, 1997, the so called “mailbox” patents, was published in the official patent gazette on September 10th, 2013. On September 11th,…
(BW) Teva and Mylan Settle Copaxone(R) Patent Litigation in France, the UK and the Netherlands, Posted on The Wall Street Journal JERUSALEM–(BUSINESS WIRE)–November 25, 2013– Teva Pharmaceutical Industries (NYSE:TEVA) and Mylan Inc. (NASDAQ:MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone(R) (glatiramer acetate) in the United…
Another Roche move against biosimilars: Kadcyla now approved in EU, Posted on Biosilimar News Roche today announced that Kadcyla (trastuzumab emtansine or T-DM1), the latest targeted medicine from its HER2 franchise and its first antibody-drug conjugate, has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer. Specifically, Kadcyla is indicated as a…
